Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Munn

Showing results (71-80 of 185) with videos related to

Pageof 19
Sort By:
Annals of the New York Academy of Sciences|June 26, 2002
Immune response to engineered tissues and cells: breakout session summaryDavid M Harlan, Dennis W Metzger, Christopher L Karp, et al.
Molecular Cancer Therapeutics|June 10, 2010
Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenaseRichard Metz, James B Duhadaway, Sonja Rust, et al.
Blood|August 4, 2012
Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapyZhi-Chun Ding, Lei Huang, Bruce R Blazar, et al.
Journal of Reproductive Immunology|October 19, 2002
Indoleamine 2,3-dioxygenase, immunosuppression and pregnancyAndrew L Mellor, Phillip Chandler, Geon Kook Lee, et al.
Immunity|May 17, 2005
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenaseDavid H Munn, Madhav D Sharma, Babak Baban, et al.
Journal of Cellular Physiology|July 31, 2010
αVβ3 integrin regulates macrophage inflammatory responses via PI3 kinase/Akt-dependent NF-κB activationAlexander S Antonov, Galina N Antonova, David H Munn, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|September 1, 1996
Monocyte-induced downregulation of nitric oxide synthase in cultured aortic endothelial cellsN Marczin, A Antonov, A Papapetropoulos, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 29, 2009
IDO activates regulatory T cells and blocks their conversion into Th17-like T cellsBabak Baban, Phillip R Chandler, Madhav D Sharma, et al.
The Biochemical Journal|June 5, 2008
Interaction of tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of the transporter as a drug target for cancer chemotherapySenthil Karunakaran, Nagavedi S Umapathy, Muthusamy Thangaraju, et al.
Science (New York, N.Y.)|August 26, 1998
Prevention of allogeneic fetal rejection by tryptophan catabolismD H Munn, M Zhou, J T Attwood, et al.
Pageof 19

Showing results (71-80 of 185) with videos related to

Sort By:
Pageof 19
Annals of the New York Academy of Sciences|June 26, 2002
Immune response to engineered tissues and cells: breakout session summaryDavid M Harlan, Dennis W Metzger, Christopher L Karp, et al.
Molecular Cancer Therapeutics|June 10, 2010
Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenaseRichard Metz, James B Duhadaway, Sonja Rust, et al.
Blood|August 4, 2012
Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapyZhi-Chun Ding, Lei Huang, Bruce R Blazar, et al.
Journal of Reproductive Immunology|October 19, 2002
Indoleamine 2,3-dioxygenase, immunosuppression and pregnancyAndrew L Mellor, Phillip Chandler, Geon Kook Lee, et al.
Immunity|May 17, 2005
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenaseDavid H Munn, Madhav D Sharma, Babak Baban, et al.
Journal of Cellular Physiology|July 31, 2010
αVβ3 integrin regulates macrophage inflammatory responses via PI3 kinase/Akt-dependent NF-κB activationAlexander S Antonov, Galina N Antonova, David H Munn, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|September 1, 1996
Monocyte-induced downregulation of nitric oxide synthase in cultured aortic endothelial cellsN Marczin, A Antonov, A Papapetropoulos, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 29, 2009
IDO activates regulatory T cells and blocks their conversion into Th17-like T cellsBabak Baban, Phillip R Chandler, Madhav D Sharma, et al.
The Biochemical Journal|June 5, 2008
Interaction of tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of the transporter as a drug target for cancer chemotherapySenthil Karunakaran, Nagavedi S Umapathy, Muthusamy Thangaraju, et al.
Science (New York, N.Y.)|August 26, 1998
Prevention of allogeneic fetal rejection by tryptophan catabolismD H Munn, M Zhou, J T Attwood, et al.
Pageof 19